HRMY.US Harmony Biosciences Holdings

Healthcare Pharmaceuticals USA Stocks
33.76 USD
Close of Nov 15, 2026
25.90 43.49
Market cap
USD 1.98B
P/E
11.2x
P/B
1.85x
ROE
19.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is HRMY.US undervalued?

Graham number
Price33.76
Graham value35.23
Discount4.2%

HRMY.US trades 4.2% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Harmony Biosciences Holdings fundamental analysis

No fundamental analysis for Harmony Biosciences Holdings yet.

Harmony Biosciences Holdings stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Harmony Biosciences Holdings

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); i…

Full company profile